Medical isotope developer IsoRay Medical is highlighting findings from a prospective trial that assessed the efficacy and safety of brain brachytherapy at the Society of Neuro-Oncology Conference on Meningioma in Toronto.
Dr. David Brachman from the University of Arizona and colleagues investigated a new way of delivering cesium-131 brachytherapy to the brain that involves embedding the seeds in collagen tiles and applying them to brain tissue after the tumor has been removed, IsoRay said. The study included 16 patients and 20 tumors.
The researchers found that 95% of the treated tumors did not recur at the surgical site. Only two of the 20 treatments resulted in radiation side effects to the brain, a problem that has occurred in previous attempts to perform brain brachytherapy, they said.
